v3.24.0.1
Document and Entity Information - USD ($)
 12 Months Ended
Dec. 31, 2023
Feb. 23, 2024
Jun. 30, 2023
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2023    
Entity File Number 001-38944    
Entity Registrant Name Akero Therapeutics, Inc.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 81-5266573    
Entity Address, Address Line One 601 Gateway Boulevard, Suite 350    
Entity Address, City or Town South San Francisco    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 94080    
Document Financial Statement Error Correction [Flag] false    
City Area Code 650    
Local Phone Number 487‑6488    
Title of 12(b) Security Common Stock, par value $0.0001 per share    
Trading Symbol AKRO    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
ICFR Auditor Attestation Flag true    
Entity Common Stock, Shares Outstanding   56,297,528  
Entity Public Float     $ 2,517,511,353
Entity Central Index Key 0001744659    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2023    
Document Fiscal Period Focus FY    
Amendment Flag false    
Auditor Name Deloitte & Touche LLP    
Auditor Firm ID 34    
Auditor Location Morristown, NJ    
Documents Incorporated by Reference [Text Block]

Part III of this Annual Report on Form 10-K incorporates by reference certain information from the registrant’s definitive Proxy Statement for its 2024 annual meeting of shareholders, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant’s fiscal year end of December 31, 2023. Except with respect to information specifically incorporated by reference in this Form 10-K, the Proxy Statement is not deemed to be filed as part of this Form 10-K.